Impact of SARS-CoV-2 vaccination and monoclonal antibodies on
outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA
survey

J 2023

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

DOESUM, Jaap A van, Jon SALMANTON-GARCIA, Francesco MARCHESI, Di Blasi ROBERTA, Iker FALCES-ROMERO et. al.

Základní údaje

Originální název

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

Autoři

DOESUM, Jaap A van, Jon SALMANTON-GARCIA, Francesco MARCHESI, Di Blasi ROBERTA, Iker FALCES-ROMERO, Alba CABIRTA, Francesca FARINA, Caroline BESSON, Barbora WEINBERGEROVÁ (203 Česká republika, domácí), Van Praet JENS, Martin SCHOENLEIN, Alberto LOPEZ-GARCIA, Sylvain LAMURE, Anna GUIDETTI, De Ramon-Sanchez CRISTINA, Josip BATINIC, Eleni GAVRIILAKI, Athanasios TRAGIANNIDIS, Maria Chiara TISI, Gaetan PLANTEFEVE, Verena PETZER, Irati ORMAZABAL-VELEZ, de Almeida Joyce MARQUES, Monia MARCHETTI, Johan MAERTENS, Marina MACHADO, Austin KULASEKARARAJ, Jose-angel HERNANDEZ-RIVAS, Maria Gomes da SILVA, Noemi FERNANDEZ, Ildefonso ESPIGADO, Lubos DRGONA, Giulia DRAGONETTI, Elisabetta METAFUNI, Maria CALBACHO, Ola BLENNOW, Dominik WOLF, van Anrooij BJORN, Raquel Nunes RODRIGUES, Anna NORDLANDER, Juan-Alberto MARTIN-GONZALEZ, Raphael LIEVIN, Moraima JIMENEZ, Stefanie K GRAFE, Ramon GARCIA-SANZ, Raul CORDOBA, Laman RAHIMLI, van Meerten TOM, Oliver A CORNELY a Livio PAGANO

Vydání

Blood advances, AMSTERDAM, ELSEVIER, 2023, 2473-9529

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.500 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133401

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1182/bloodadvances.2022009578

UT WoS

001023671100001

Klíčová slova anglicky

SARS-CoV-2 vaccination; post–CD19-directed CAR T-cell therapy

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 2. 2024 09:14, Mgr. Tereza Miškechová

Anotace

V originále

Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www. clinicaltrials.gov as #NCT04733729.

Citovat

DOESUM, Jaap A van, Jon SALMANTON-GARCIA, Francesco MARCHESI, Di Blasi ROBERTA, Iker FALCES-ROMERO, Alba CABIRTA, Francesca FARINA, Caroline BESSON, Barbora WEINBERGEROVÁ, Van Praet JENS, Martin SCHOENLEIN, Alberto LOPEZ-GARCIA, Sylvain LAMURE, Anna GUIDETTI, De Ramon-Sanchez CRISTINA, Josip BATINIC, Eleni GAVRIILAKI, Athanasios TRAGIANNIDIS, Maria Chiara TISI, Gaetan PLANTEFEVE, Verena PETZER, Irati ORMAZABAL-VELEZ, de Almeida Joyce MARQUES, Monia MARCHETTI, Johan MAERTENS, Marina MACHADO, Austin KULASEKARARAJ, Jose-angel HERNANDEZ-RIVAS, Maria Gomes da SILVA, Noemi FERNANDEZ, Ildefonso ESPIGADO, Lubos DRGONA, Giulia DRAGONETTI, Elisabetta METAFUNI, Maria CALBACHO, Ola BLENNOW, Dominik WOLF, van Anrooij BJORN, Raquel Nunes RODRIGUES, Anna NORDLANDER, Juan-Alberto MARTIN-GONZALEZ, Raphael LIEVIN, Moraima JIMENEZ, Stefanie K GRAFE, Ramon GARCIA-SANZ, Raul CORDOBA, Laman RAHIMLI, van Meerten TOM, Oliver A CORNELY a Livio PAGANO. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood advances. AMSTERDAM: ELSEVIER, 2023, roč. 7, č. 11, s. 2645-2655. ISSN 2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2022009578.

@article{2368940,
   author = {Doesum, Jaap A van and SalmantonandGarcia, Jon and Marchesi, Francesco and Roberta, Di Blasi and FalcesandRomero, Iker and Cabirta, Alba and Farina, Francesca and Besson, Caroline and Weinbergerová, Barbora and Jens, Van Praet and Schoenlein, Martin and LopezandGarcia, Alberto and Lamure, Sylvain and Guidetti, Anna and Cristina, De RamonandSanchez and Batinic, Josip and Gavriilaki, Eleni and Tragiannidis, Athanasios and Tisi, Maria Chiara and Plantefeve, Gaetan and Petzer, Verena and OrmazabalandVelez, Irati and Marques, de Almeida Joyce and Marchetti, Monia and Maertens, Johan and Machado, Marina and Kulasekararaj, Austin and HernandezandRivas, Joseandangel and Silva, Maria Gomes da and Fernandez, Noemi and Espigado, Ildefonso and Drgona, Lubos and Dragonetti, Giulia and Metafuni, Elisabetta and Calbacho, Maria and Blennow, Ola and Wolf, Dominik and Bjorn, van Anrooij and Rodrigues, Raquel Nunes and Nordlander, Anna and MartinandGonzalez, JuanandAlberto and Lievin, Raphael and Jimenez, Moraima and Grafe, Stefanie K and GarciaandSanz, Ramon and Cordoba, Raul and Rahimli, Laman and Tom, van Meerten and Cornely, Oliver A and Pagano, Livio},
   article_location = {AMSTERDAM},
   article_number = {11},
   doi = {http://dx.doi.org/10.1182/bloodadvances.2022009578},
   keywords = {SARS-CoV-2 vaccination; post–CD19-directed CAR T-cell therapy},
   language = {eng},
   issn = {2473-9529},
   journal = {Blood advances},
   title = {Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey},
   url = {https://ashpublications.org/bloodadvances/article/7/11/2645/495340/Impact-of-SARS-CoV-2-vaccination-and-monoclonal},
   volume = {7},
   year = {2023}
}

TY  - JOUR
ID  - 2368940
AU  - Doesum, Jaap A van - Salmanton-Garcia, Jon - Marchesi, Francesco - Roberta, Di Blasi - Falces-Romero, Iker - Cabirta, Alba - Farina, Francesca - Besson, Caroline - Weinbergerová, Barbora - Jens, Van Praet - Schoenlein, Martin - Lopez-Garcia, Alberto - Lamure, Sylvain - Guidetti, Anna - Cristina, De Ramon-Sanchez - Batinic, Josip - Gavriilaki, Eleni - Tragiannidis, Athanasios - Tisi, Maria Chiara - Plantefeve, Gaetan - Petzer, Verena - Ormazabal-Velez, Irati - Marques, de Almeida Joyce - Marchetti, Monia - Maertens, Johan - Machado, Marina - Kulasekararaj, Austin - Hernandez-Rivas, Jose-angel - Silva, Maria Gomes da - Fernandez, Noemi - Espigado, Ildefonso - Drgona, Lubos - Dragonetti, Giulia - Metafuni, Elisabetta - Calbacho, Maria - Blennow, Ola - Wolf, Dominik - Bjorn, van Anrooij - Rodrigues, Raquel Nunes - Nordlander, Anna - Martin-Gonzalez, Juan-Alberto - Lievin, Raphael - Jimenez, Moraima - Grafe, Stefanie K - Garcia-Sanz, Ramon - Cordoba, Raul - Rahimli, Laman - Tom, van Meerten - Cornely, Oliver A - Pagano, Livio
PY  - 2023
TI  - Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
JF  - Blood advances
VL  - 7
IS  - 11
SP  - 2645-2655
EP  - 2645-2655
PB  - ELSEVIER
SN  - 24739529
KW  - SARS-CoV-2 vaccination
KW  - post–CD19-directed CAR T-cell therapy
UR  - https://ashpublications.org/bloodadvances/article/7/11/2645/495340/Impact-of-SARS-CoV-2-vaccination-and-monoclonal
N2  - Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www. clinicaltrials.gov as #NCT04733729.
ER  -

DOESUM, Jaap A van, Jon SALMANTON-GARCIA, Francesco MARCHESI, Di Blasi ROBERTA, Iker FALCES-ROMERO, Alba CABIRTA, Francesca FARINA, Caroline BESSON, Barbora WEINBERGEROVÁ, Van Praet JENS, Martin SCHOENLEIN, Alberto LOPEZ-GARCIA, Sylvain LAMURE, Anna GUIDETTI, De Ramon-Sanchez CRISTINA, Josip BATINIC, Eleni GAVRIILAKI, Athanasios TRAGIANNIDIS, Maria Chiara TISI, Gaetan PLANTEFEVE, Verena PETZER, Irati ORMAZABAL-VELEZ, de Almeida Joyce MARQUES, Monia MARCHETTI, Johan MAERTENS, Marina MACHADO, Austin KULASEKARARAJ, Jose-angel HERNANDEZ-RIVAS, Maria Gomes da SILVA, Noemi FERNANDEZ, Ildefonso ESPIGADO, Lubos DRGONA, Giulia DRAGONETTI, Elisabetta METAFUNI, Maria CALBACHO, Ola BLENNOW, Dominik WOLF, van Anrooij BJORN, Raquel Nunes RODRIGUES, Anna NORDLANDER, Juan-Alberto MARTIN-GONZALEZ, Raphael LIEVIN, Moraima JIMENEZ, Stefanie K GRAFE, Ramon GARCIA-SANZ, Raul CORDOBA, Laman RAHIMLI, van Meerten TOM, Oliver A CORNELY a Livio PAGANO. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. \textit{Blood advances}. AMSTERDAM: ELSEVIER, 2023, roč.~7, č.~11, s.~2645-2655. ISSN~2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2022009578.

Podrobný výpis o publikaci